bioAffinity Technologies (NASDAQ:BIAF) Stock Rating Lowered by Wall Street Zen

bioAffinity Technologies (NASDAQ:BIAF – Get Free Report) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a note issued to investors on Saturday, Wall Street Zen reports.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of bioAffinity Technologies in a research report on Friday, October 16th. One analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, the company currently has a consensus rating of “Sell”.

Read Our Latest Report on bioAffinity Technologies

bioAffinity Technologies Price Performance

bioAffinity Technologies stock opened at $2.20 on Friday. The company has a current ratio of 1.51, a quick ratio of 1.47 and a debt-to-equity ratio of 0.13. The company has a market capitalization of $4.00 million, a PE ratio of -0.05 and a beta of -1.03. bioAffinity Technologies has a 12 month low of $2.17 and a 12 month high of $80.70. The stock has a 50-day moving average price of $5.36 and a two-hundred day moving average price of $18.25.

bioAffinity Technologies (NASDAQ:BIAF – Get Free Report) last announced its quarterly earnings results on Friday, November 6th. The company reported ($5.89) EPS for the quarter, beating analysts’ consensus estimates of ($31.50) by $25.61. bioAffinity Technologies had a negative return on equity of 293.44% and a negative net margin of 278.90%. The firm had revenue of $1.07 million for the quarter, compared to analyst estimates of $1.91 million.

bioAffinity Technologies Company Profile

(Get Free Report)

bioAffinity Technologies, Inc. is a biotechnology company focused on developing diagnostic and therapeutic products for cancer and other serious diseases. The company’s platform uses porphyrin-based compounds designed to selectively identify or target abnormal cells, with the goal of supporting earlier disease detection and more precise treatment. Its lead diagnostic product, CyPath Lung, is an investigational, noninvasive urine test intended to aid in the detection of lung cancer. The test uses an inhaled porphyrin compound that can bind to cancer cells in the lungs; the resulting material is collected in urine and analyzed using laboratory methods.

Further Reading

Receive News & Ratings for bioAffinity Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bioAffinity Technologies and related companies with MarketBeat.com's FREE daily email newsletter.